Infectious Diseases Biomarker Testing Market by Product (Assays, Platforms); by Application (Respiratory Infection, Bloodstream and Hospital-Acquired Infection, Sexually Transmitted Infection, Gastro-Intestinal Infection, Urinary Tract Infection, Central Nervous System Infection, Other); by Technology (PCR, ELISA, or EIA, NGS, IHC, ISH, Others); by Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa): Global Forecasts 2021 To 2027

The Global Infectious Diseases Biomarker Testing Market was valued at USD 5.1 Bn in 2020 and is expected to reach USD 13.5 Bn by 2027, with a growing CAGR of 15.0 % during the forecast period

Increase in number of emerging infectious diseases continue to affect the social, mental, and economical aspects across the globe. According to WHO, out of top ten infectious diseases, three diseases is responsible for the death, which include, respiratory, diarrheal and tuberculosis. These diseases collectively account for more than 6 million deaths yearly. Despite of availability of immense control on the occurrence of diseases, people continue to suffer and cause diseases threats in the form of epidemic, outbreak, or pandemic.

Diagnosis is the foremost step in treating the diseases. There has been extensive development in the field of diagnosis and rising awareness regarding importance of early diagnosis. Biomarker testing has evolved as one of the most precise, accurate and informative testing procedures. Owing to current scenario of covid-19 outbreak, the global infectious diseases biomarker testing market is expected to grow high during the forecast period.

An advancement in biomarker testing procedures such as high speed, sensitivity, patient compliance and external funding for research execution fuels the growth of infectious diseases biomarker testing market. Moreover, growth in infectious diseases biomarker testing products, adoption of multiplexing technologies and increase in number of CRO’s is expected to show a significant growth during forecast period. Entry of new testing procedures & key players and launch of new biomarker testing product is expected to boost the growth of infectious diseases biomarker testing market in the near future.

Infectious Diseases Biomarker Testing Market Segmentation

By Product

• Assay
• Platforms

By Application

• Respiratory Infection
• Bloodstream and Hospital-Acquired Infection
• Sexually Transmitted Infection
• Gastro-Intestinal Infection
• Urinary Tract Infection
• Central Nervous System Infection
• Other

By Technology

• PCR
• ELISA or EIA
• NGS
• IHC
• ISH
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Based on product, assays held the highest share in infectious diseases biomarker testing market due to availability of diverse range of assays in addition to booming research activities

Based on product, infectious diseases biomarker testing market is broadly segmented into assays and platforms. Assays hold the maximum market share due to high demand for research activities and presence of vast varieties of assays offered by key companies.

Based on application, blood stream and hospital-acquired infection hold the largest share in infectious diseases biomarker testing market due to increase in rate of hospital-based infections

Based on application, infectious diseases biomarker testing market segment include respiratory infection, bloodstream, and hospital-acquired infection, sexually transmitted infection, gastro-intestinal infection, urinary tract infection and central nervous system infection. Blood stream and hospital acquired infection has emerged as important public health concern and considered to be the leading cause of mortality & morbidity. Increase in rate of infections, rising geriatric population, growing health & personal hygiene drives the growth of infectious diseases biomarker testing market.

Based technology, PCR dominated the infectious diseases biomarker testing market in 2020 due to increase in demand for its diagnosis application during covid-19

Based on technology, infectious diseases biomarker testing market is broadly segmented into PCR, ELISA or EIA, NGS, IHC and ISH. PCR accounted for the highest market share in 2020 due to rise in its demand for diagnosis of various infectious diseases such as covid-19, viral flu etc. PCR technology is widely available & acceptable across globe. Parameters such as high throughput sensitivity and test result accuracy tend to increase the demand of PCR segment in infectious diseases biomarker testing market.

During covid-19 outbreak, PCR technology has gained huge importance in diagnosis of viral infectious diseases. PCR technology has wide application in DNA/RNA sequencing and genetic testing.

Based on geographical region, North America led the infectious diseases biomarker testing market in 2020 due to increase in incidence of infectious diseases in this region

Geographically, North America accounted for the highest market share in 2020 and expected to increase more during forecast period due to increase in prevalence of infectious diseases, increase in healthcare expenditure and ever rising population led to increase in demand for infectious diseases biomarker testing market. Moreover, presence of large number of key players & manufacturing units such as Becton Dickinson, Bio-Rad Laboratories etc in this region drives the growth of infectious diseases biomarker testing market.

Company Profiles and Competitive Intelligence

The key players operating in the infectious diseases biomarker testing market are:

• Abbott Laboratories
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• bioMrieux SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• PerkinElmer, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Seegene Inc
• Co-Diagnostics, Inc.
• ELITechGroup
• Epitope Diagnostics, Inc
• Abacus Diagnostical Oy
•  ALPCO
• Quest Diagnostics Incorporated
• Epitope Diagnostics, Inc.
•  Trivitron Healthcare
•  Meril Life Sciences Pvt. Ltd.
•  InBios International, Inc.  

The report also provides an in-depth analysis of infectious diseases biomarker testing market dynamics such as drivers, restraints, opportunities, and challenges

Drivers

• Increase in burden of the growing rate of infectious diseases
• Advancements in molecular techniques and biomarker testing procedures
• Increase in product approvals and launches
• Increase in government funding for research activities
• Booming clinical diagnostics test market
• Rise in usage of biomarker test in healthcare professionals

Restraints

• Stringent government policies for product approvals
• Poorly suited reimbursement policies
• High capital investment in testing procedures

Opportunities

• Increase in demand for next-generation sequencing and demand for biomarkers
• Rise in spread of CRO’s specializing in infectious diseases
• Exploring untapped market of developing countries create vast opportunities

Challenges

• Emergence of innovative testing procedures
• Belligerent product launch by the companies
• Lack of high-complexity testing centers

COVID-19 Impact on the  Infectious Diseases Biomarker Testing Market Analysis

Covid-19 has highly affected the industries in terms of growth, economy, health and mental wellbeing of every individual. In this challenging situation, every industry is trying to give best services in terms of quality and safety. Initially times of covid-19 outbreak has badly impacted the supply of raw materials, equipment's and products across the world. Government granted restrictions on movement inter or inter country to prevent the spread of infectious diseases.

Early covid-19 diagnosis became important in the market to prevent spread of infection. The most commonly diagnostic test used was PCR. PCR gained huge importance during covid outbreak. For instance, covid-19 outbreak has largely increased the demand for molecular diagnostics testing tools and anticipate the growth of infectious diseases biomarker testing market in coming years.

The report also provides an in-depth analysis of key trends in infectious diseases biomarker testing market

• The lockdown and restrictions related to social distancing and movement implemented by government in COVID-19 countries had negatively impacted the supply chain of diagnostic & biomarker testing tools and affected the growth of infectious diseases biomarker testing market
• Increase in government initiatives, development in innovative diagnostics techniques or biomarker testing tools & kits drives the growth of infectious diseases biomarker testing market

The report also provides an in-depth analysis of recent news developments and investments in the infectious diseases biomarker testing

• In April 2021, Hologic acquired Mobidiag Oy, a commercial stage developer of innovative molecular diagnostics test at USD 795 Mn to expand its portfolio and develop PCR-based tests for acute care condition for infectious diseases.
• In January 2018, Charles River acquired KWS BioTest, a leader in CRO’s specialized in in-vitro and in-vivo testing service for infectious diseases. This acquisition is aimed to enhance Charles River’s discovery expertise and provide additional tools in active therapeutic research.

The unique insights provided by this report also includes the following:

• In-depth Value Chain Analysis
• Opportunity Mapping
• Sector Snapshot
• Key Players Positioning Matrix
• Regulatory Scenario
• Strategies Adopted-benchmarking Heat Map
• Market Trends
• Covid-19 Impact Analysis
• Product Comparison
• Pre & Post COVID 19 Impacts on Infectious Diseases Biomarker Testing Market
• Competitive Landscape

Frequently Asked Questions (FAQs)

Related Reports